A kitten stranded on an overpass for at least three weeks was rescued by a group of concerned citizens and a team of ...

At Tom's Guide, we've tried them all. From cognitive shuffling to the military method and the 4-7-8 method, we're big fans of ...

Before seafaring and air travel took over, we had bridges to connect us all. In many ways, they’ve helped shape communities ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public by merging with a Cormorant-sponsored SPAC.

BridgeBio Oncology has entered into a merger agreement with Helix Acquisition Corp II to form a combined entity.

BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the formation of a combined entity known as BridgeBio Oncology Therapeutics.

BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with Helix Acquisition Corp. II (NASDAQ:HLXB), a Boston-headquartered SPAC ...

In addition to approximately $196 million held in Helix Acquisition Corp. II’s trust account (assumed as of the closing and assuming no redemptions by Helix’s public shareholders), the ...

The merger agreement announced Friday is with Helix Acquisition Corp. II, a SPAC sponsored by affiliates of Cormorant Asset Management. When the deal closes, the combined company will take the ...

In a deal announced Friday, BridgeBio Oncology expects to get around $450 million by combining with Helix Acquisition Corp., a special purpose acquisition company, or SPAC, formed by biotech investor ...